Achieve Life Sciences (ACHV) Common Equity (2010 - 2026)

Achieve Life Sciences has disclosed Common Equity across 17 years of filings, most recently posting $10.7 million for Q1 2026.

• Quarterly Common Equity rose 3.88% year-over-year to $10.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $10.7 million (up 3.88% YoY) and the FY2025 annual result came in at $21.5 million, up 2.96% from the prior year.
• Common Equity slipped to $10.7 million in Q1 2026, from $21.5 million in the prior quarter.
• Over five years, Common Equity peaked at $49.5 million in Q1 2024 and troughed at -$1.4 million in Q4 2023.
• A 5-year average of $18.7 million and a median of $13.2 million in 2022 frame the typical range for Common Equity.
• Annual changes were most pronounced in 2023 — Common Equity slumped 117.44% — and 2024, when it soared 11063.88%.
• Tracing ACHV's Common Equity over 5 years: stood at $8.3 million in 2022, then sank by 117.44% to -$1.4 million in 2023, then jumped by 1543.3% to $20.9 million in 2024, then rose by 2.96% to $21.5 million in 2025, then sank by 50.38% to $10.7 million in 2026.
• Business Quant data shows ACHV's Common Equity at $10.7 million in Q1 2026, $21.5 million in Q4 2025, and $33.6 million in Q3 2025.